Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Colorectal cancer (CRC) in Egypt is advanced tumors at diagnosis. Although, the dramatic
increase in efficacy, reduction of mortality, and improvements in survival by the use of
standard doses of chemotherapy, some CRC patients suffer from severe toxicities besides
disease progression. Use of chemotherapy less than the maximum tolerated dose, with no
prolonged drug free breaks incapacitates the cells to engage in progression mechanisms,
suggesting that it could be a better alternative to standard dose therapy with better
toxicity profile